|
Post by mnholdem on Aug 14, 2014 13:13:54 GMT -5
For some reason I woke up Sun. night around 3AM and went online and saw the news. Saw all kinds of people celebrating on the other board . My first reaction was the opposite, I thought it was terrible for MNKD. But as I thought about it, Can this really be the whole deal? Did we really need Greenhill to get this? Heck 2 attorneys could have put this together over beers in an evening (with the MNKD attorney getting drunk faster). Then I listened to both calls. But the 2nd one was the most interesting. Matt being vague, not knowing the share count (Come on!), etc. There was no talk at all of Technosphere and we still don't know how long the agreement is for. (Or did I miss that)! Then there was Al's slip up which was really all he said. And we are giving SNY the process? ? Surely, this can't be all there is to it. I think there is another shoe(s) to drop. If you listened to Al in both conferences, he sounds like he is slipping a bit. Didn't seem his sharp, gregarious old self. Just my theory, but I think the remaining 35% of "A" along with the whole patent ownership, technoshere, etc. will be sold. Al accomplished his goal to get "A' out to the diabetic population with the best choice out there. I think he sells off and maybe does consulting at the most. The deal was too bad for there not to be a 2nd or 3rd step. At least I hope so!!!!!! I also found it interesting that on Greenhill's Recent transaction list we are still listed as pending with no $ amount. Just my hope and opinion. I hate to say it, but right now we may still be over valued.
FORM 10-Q ITEM 5: OTHER INFORMATION
Concludes with : The foregoing description is only a summary of the Sanofi License Agreement and the second amendment to the Facility Agreement and is qualified in its entirety by the terms of the Sanofi License Agreement and the second amendment to the Facility Agreement, copies of which will be filed as exhibits to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.
I haven't had time to download the transcript, but I did listen in to both cc's and recall Matt saying that this deal, if you were to factor in the financial ramifications, is more of a 50/50 for Mannkind. Perhaps somebody can confirm that statement, but nonetheless Matt did make the remark that this deal will completely change Mannkind's financial reports.
There is a lot of missing information that is not being disclosed. I think this deal may be much more sophisticated than we, or Wall Street pundits, can possible imagine at this time.
Hopefully Matt will clarify his remarks, but since Matt does wear multiple hats, Investor Relations has never been his strong suit. So we might have to wait until the EOQ3 conference to valuate the deal.
My point, Daduke, is that I think your gut instinct is spot on that there is another shoe about to drop. I hope it's a size 14.
|
|
|
Post by bradleysbest on Aug 14, 2014 13:20:14 GMT -5
With steel toes!
|
|
|
Post by daduke38 on Aug 14, 2014 13:27:05 GMT -5
I really do have that feeling!! Too many details that Matt couldn't elaborate on. Was also pretty much his standard answer to most questions.
|
|
|
Post by bradleysbest on Aug 14, 2014 13:36:11 GMT -5
Agree, Al is too sharp for these dudes! Something is coming down the road .....
|
|
|
Post by mnholdem on Aug 14, 2014 13:59:56 GMT -5
I also wonder about daduke's reading of Al being a little off.
Could it be that Al is just completely frustrated at not being allowed to disclose hardly anything at this time? He seemed so eager to jump in and spill the beans. Matt had to verbally muzzle him.
We know how Al feels about Afrezza from the many interviews he conducted. It must be driving him nuts to have to keep his mouth shut. I mean, imagine if Pierre told Al that Sanofi expects initial sales of $2 billion in 2015 and Al sees how stock is currently tumbling, how shareholders want information but he is being restrained and just has to sit tight and say... nothing?
|
|
|
Post by dreamboatcruise on Aug 14, 2014 14:23:36 GMT -5
It's a shame that Sanofi's earnings call is so far off. One would think they are going to have to have some answers for analyst questions along the lines of "You just committed to spending nearly a billion dollars on the rights to Afrezza... can you provide some insight into sales and when this will be accretive?"
Here is one guess at a scenario. The deal was purposely held off until after Sanofi's last earnings so that they could get an extra quarter in without having to face questions, thus being able to keep spending, timeline, etc. secrete and giving competitors less time to react once they, hopefully, give some insight into how great this deal will be for both them and MNKD when they next have an earnings call.
Though I don't discount the possibility I'm merely engaging in the 3rd stage of grief by creating a back story to avoid progressing to depression.
|
|
|
Post by gamblerjag on Aug 14, 2014 14:49:14 GMT -5
verbalize muzzle.. lol
|
|
|
Post by chauffe00 on Aug 14, 2014 15:44:25 GMT -5
FORM 10-Q ITEM 5: OTHER INFORMATION
Concludes with : The foregoing description is only a summary of the Sanofi License Agreement and the second amendment to the Facility Agreement and is qualified in its entirety by the terms of the Sanofi License Agreement and the second amendment to the Facility Agreement, copies of which will be filed as exhibits to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.
I haven't had time to download the transcript, but I did listen in to both cc's and recall Matt saying that this deal, if you were to factor in the financial ramifications, is more of a 50/50 for Mannkind. Perhaps somebody can confirm that statement, but nonetheless Matt did make the remark that this deal will completely change Mannkind's financial reports.
There is a lot of missing information that is not being disclosed. I think this deal may be much more sophisticated than we, or Wall Street pundits, can possible imagine at this time.
Hopefully Matt will clarify his remarks, but since Matt does wear multiple hats, Investor Relations has never been his strong suit. So we might have to wait until the EOQ3 conference to valuate the deal.
My point, Daduke, is that I think your gut instinct is spot on that there is another shoe about to drop. I hope it's a size 14.
oh how I wish - one things for sure I wish I was a better trader - i missed a trading opp to sell and buy back...still a lot of unanswered questions - and I think with greenhill being invloved there has to be more to the puzzle...
|
|
|
Post by bradleysbest on Aug 14, 2014 15:47:59 GMT -5
I missed out to... Could have sold & bought a bunch more shares! Oh well
|
|
|
Post by goyocafe on Aug 14, 2014 16:24:47 GMT -5
It's a shame that Sanofi's earnings call is so far off. One would think they are going to have to have some answers for analyst questions along the lines of "You just committed to spending nearly a billion dollars on the rights to Afrezza... can you provide some insight into sales and when this will be accretive?" Here is one guess at a scenario. The deal was purposely held off until after Sanofi's last earnings so that they could get an extra quarter in without having to face questions, thus being able to keep spending, timeline, etc. secrete and giving competitors less time to react once they, hopefully, give some insight into how great this deal will be for both them and MNKD when they next have an earnings call. Though I don't discount the possibility I'm merely engaging in the 3rd stage of grief by creating a back story to avoid progressing to depression. Could they be holding off so they can announce a Q4 launch? (This board does allow for far fetched thoughts, right?)
|
|
|
Post by gamblerjag on Aug 14, 2014 16:42:56 GMT -5
q4 launch? I swear I heard Matt say on the call... q1 or earlier.
|
|
|
Post by goyocafe on Aug 14, 2014 17:02:57 GMT -5
q4 launch? I swear I heard Matt say on the call... q1 or earlier. I guess I should have been more clear. Q4, 2014.
|
|
|
Post by cybergym66 on Aug 14, 2014 17:12:45 GMT -5
MNKD has been really tight-lipped about future plans...that's good if they spring something on us soon (within the next few weeks or so). So the question is what?
|
|
|
Post by dreamboatcruise on Aug 14, 2014 17:20:15 GMT -5
MNKD has been really tight-lipped about future plans...that's good if they spring something on us soon (within the next few weeks or so). So the question is what? An inhaled drug to suppress unfounded wishful thinking?
|
|
|
Post by cybergym66 on Aug 14, 2014 17:28:44 GMT -5
MNKD has been really tight-lipped about future plans...that's good if they spring something on us soon (within the next few weeks or so). So the question is what? An inhaled drug to suppress unfounded wishful thinking? BINGO!!! (Don't take my previous statement to mean I believe/wish for an early sales start. 1st Qtr is what MNKD/Sanofi are targeting)
|
|